By Callum Keown

One person's trash is another person's treasure.

After Nvidia revealed it sold its entire stake in Recursion Pharmaceuticals, Cathie Wood's ARK snapped up the drug-discovery company's shares Wednesday.

The AI chip maker's exit, disclosed in its 13-F filing, initially hit the pharma company's shares -- Recursion stock was 14% down for the day at one point before recovering to close 2% higher. It seems the slump brought on a healthy dose of dip-buying. The shares were up 5% in early trading Thursday.

ARK Invest has been building its position in Recursion in recent months and took the opportunity to buy more of the stock. The company bought 1.25 million shares of Recursion across two of its exchange-traded funds (ETFs), according to a trading notification for Wednesday.

The ARK Innovation ETF now holds 21.8 million shares of Recursion, worth around $77 million, according to the company's website. Nvidia's stake was smaller -- it held 7.71 million shares at the end of the third quarter before exiting its position entirely as of Dec. 31 last year.

It isn't clear exactly when in the fourth quarter Nvidia sold its stake but Recursion stock has fallen 14% so far in 2026, as of Wednesday's close. The shares are down 68% over the past year.

So the AI chip maker wanted out but Cathie Wood and others clearly want in. Wall Street isn't so sure -- just 38% of analysts covering the stock have a Buy rating. Though, its average price target of $7 implies a 98% jump from here.

That would be some pot of gold.

Write to Callum Keown at callum.keown@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 19, 2026 10:46 ET (15:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.